ABBVHealthcare · Drug Manufacturers - GeneralThe 30 Wall Street analysts covering AbbVie, Inc. hold a median 12-month price target of $285 — +6.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 6 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores AbbVie, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (99): The share price has been relatively steady.
Issuance (61): The company has been issuing shares or taking on financing, diluting existing holders.
Size (0): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ABBV, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +6.9% from it.
Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Sept 2026 | HSBC | Maintains | Buy | $300 → $315 |
| 20 Aug 2026 | Piper Sandler | Maintains | Overweight | $298 → $303 |
| 20 Aug 2026 | Piper Sandler | Maintains | Overweight | — |
| 17 Aug 2026 | Wells Fargo | Maintains | Overweight | $295 → $300 |
| 17 Aug 2026 | Wells Fargo | Maintains | Overweight | — |
| 13 Aug 2026 | Wolfe Research | Upgrade | Outperform | $300 |
| 13 Aug 2026 | Wolfe Research | Upgrade | Outperform | — |
| 11 Aug 2026 | BNP Paribas | Maintains | Neutral | $218 → $247 |
| 11 Aug 2026 | BNP Paribas | Maintains | Neutral | — |
| 10 Aug 2026 | Evercore ISI Group | Maintains | Outperform | $246 → $260 |
| 10 Aug 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 6 Aug 2026 | Berenberg | Maintains | Buy | — |
| 5 Aug 2026 | Erste Group | Upgrade | Buy | — |
| 4 Aug 2026 | Guggenheim | Maintains | Buy | — |
| 4 Aug 2026 | Guggenheim | Maintains | Buy | $261 → $288 |
| 3 Aug 2026 | Canaccord Genuity | Maintains | Buy | — |
| 3 Aug 2026 | Canaccord Genuity | Maintains | Buy | $282 → $290 |
| 3 Aug 2026 | Cantor Fitzgerald | Maintains | Overweight | $265 → $285 |
| 3 Aug 2026 | Cantor Fitzgerald | Maintains | Overweight | — |
| 3 Aug 2026 | Morgan Stanley | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ABBV appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 6 Oct 2026, AbbVie, Inc. returned +19.4% against +17.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 10% of US stocks
Cheaper than 18% of US stocks
Cheaper than 99% of US stocks
Cheaper than 19% of US stocks
Higher than 52% of US stocks
Higher than 92% of US stocks
Higher than 87% of US stocks
Higher than 92% of US stocks
Higher than 69% of US stocks
Higher than 11% of US stocks
Higher than 93% of US stocks
Higher than 83% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
AbbVie, Inc. has a market value of $464.4B and an enterprise value of $528.8B.
Revenue in the twelve months to 30 June 2026: $64.4B. The latest quarter grew 10.2% year on year.
Net income over the same four quarters: $6.3B, a 9.8% net margin.
Diluted earnings per share, trailing twelve months: $3.54.
Free cash flow in the twelve months to 30 June 2026: $18.2B.
AbbVie, Inc. spent $1.5B on share buybacks and $12.0B on dividends in the twelve months to 30 June 2026.
Trailing P/E: 74.2×; forward P/E: 16.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 2.63%, paying out 190% of earnings.
AbbVie, Inc. employs 57,000 people — $1.1M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own AbbVie, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The Motley Fool reports that an analyst sees expanded uses for Rinvoq and Skyrizi supporting a potential AbbVie share price of up to $315. The article presents this bull case as potentially strengthened by further efforts to expand AbbVie’s drug pipeline.
Why it matters — ABBV watchers may follow the drugs’ expanded uses and pipeline efforts as factors in the analyst’s outlook.
AbbVie said its epcoritamab plus R-CHOP regimen reduced the risk of progression or death by 51% in frontline diffuse large B-cell lymphoma (DLBCL), meeting the phase III study’s progression-free survival goal.
Why it matters — The phase III PFS result highlights a positive clinical-trial outcome for an AbbVie combination in frontline DLBCL.
Zacks Investment Research reports that Wall Street analysts see AbbVie (ABBV) as a buy. The excerpt notes that investors often consider analyst recommendations and that rating changes are sometimes covered in the media.
Why it matters — ABBV watchers may follow analyst recommendations and rating changes as part of their view of the stock.
The Motley Fool article notes that AbbVie has delivered solid double-digit growth in recent quarters and says additional approvals for its top drugs could support further growth.
Why it matters — ABBV watchers may follow potential drug approvals alongside the company’s recent growth.
The article says AbbVie investors who bought after headline-grabbing drug approvals consistently lagged those who bought amid fear and uncertainty. It points to a counterintuitive pattern in which milestone-related good news could be a poor entry point.
Why it matters — ABBV watchers may find the article’s account of investor performance around drug milestones relevant when interpreting how news events have related to the stock.
The 30 Wall Street analysts covering AbbVie, Inc. have a median 12-month price target of $285, with estimates ranging from $200 to $328. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 30 analysts covering AbbVie, Inc., 24 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks AbbVie, Inc. 96 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 6 Oct 2026, AbbVie, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (99 of 100).
No one can know that. What the data says: the median 12-month target from 30 analysts implies +6.9% from the last close, and Ticker Nerd's factor model ranks AbbVie, Inc. 96 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering AbbVie, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABBV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $200 to $328 over the next 12 months.
AbbVie, Inc. returned +19.4% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and commercializes medicines and therapies for complex and serious diseases.
The most recent item we track (The Motley Fool, 6 Oct 2026): "HSBC Thinks AbbVie Can Climb to $315. Here's the Bull Case in Plain English.". The Motley Fool reports that an analyst sees expanded uses for Rinvoq and Skyrizi supporting a potential AbbVie share price of up to $315. The article presents this bull case as potentially strengthened by further efforts to expand AbbVie’s drug pipeline.
AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and commercializes medicines and therapies for complex and serious diseases. AbbVie focuses on major therapeutic areas including immunology, oncology, neuroscience, eye care, aesthetics, and virology, serving patients with chronic autoimmune conditions, blood cancers, inflammatory disorders, and other specialized medical needs. The company’s portfolio includes branded prescription medicines and advanced therapies distributed through physicians, wholesalers, specialty pharmacies, healthcare facilities, and other healthcare channels. AbbVie also supports contract manufacturing services for selected biologics and pharmaceutical processes. Headquartered in North Chicago, Illinois, AbbVie operates as a research-driven healthcare business with a broad international footprint and a strong role in specialty medicine markets.
CEO Mr. Robert A. Michael CPA · 57,000 employees · United States · https://www.abbvie.com
